Influenza viruses are respiratory pathogens that cause high morbidity and mortality worldwide every year. Vaccination is one of the most effective methods to prevent influenza infection. The composition of vaccines is recommended annually by the World Health Organization (WHO) to ensure induced immune response against epidemic strain effectively[@b1]. However, systematic review and meta-analysis on the efficacy and effectiveness of influenza vaccines have shown that pooled efficacy of trivalent inactivated influenza vaccine (TIV) was only 59% in adults aged 18--65 years, which indicated a moderate protection of influenza vaccines against virologically confirmed influenza[@b2]. The protective effects of the immune response are influenced not only by the antigenic match between the vaccine strains and epidemic strains[@b3], but also by the immunocompetence of individuals[@b4][@b5][@b6][@b7]. Hence, the identification of markers that can accurately predict vaccination efficacy is a pressing need, of which the information would not only enhance the efficacy of current vaccines through personalized vaccination approaches, but would also aid in exploring important mechanisms affecting efficacy, which would in turn contribute to the rational development of next-generation vaccines[@b8].

Immunoglobulin G (IgG) is a major antibody isotype in the blood that can protect the body from infection of pathogens. The Fab region of the IgG molecule is responsible for recognizing and binding to non-self antigens, whereas the Fc region implements elimination of foreign substances by interacting with complement molecules and Fc receptors to activate the complement system and induce antibody-dependent cell-mediated cytotoxicity (ADCC)[@b9][@b10]. The N-glycan located in the Fc region has been shown to affect the binding affinity of IgG to Fc receptors and complement components[@b11][@b12][@b13][@b14]. Glycosylation pattern of Fc determined by the ratio of B cells with different types of glycosyltransferases varies between different individual IgG molecules[@b15]. When B cells are stimulated by "environmental" factors, mediators that stimulate the innate immune system, or factors arising from the adaptive immune system, Fc glycosylation could be modulated as a result of significant changes in the expression of glycosylation genes[@b16][@b17]. Since 1985, a series of studies have shown that the glycosylation of the Fc region can be used to identify a certain number of autoimmune and inflammatory diseases (e.g. rheumatoid arthritis). The glycosylation of IgG has also been shown to correlate with disease progression and clinical outcome[@b12][@b18][@b19][@b20][@b21][@b22][@b23][@b24]. These data implicit a close association between variations in the glycosylation of IgG and changes in the immune status of humans.

On the basis of aforementioned, it can be speculated that glycosylation of IgG might be altered as a result of the immune response. It has been reported that glycosylation of antigen-specific IgG1 changed upon monovalent influenza vaccination[@b25]. A recent study on the temporal response patterns to influenza vaccine revealed a distinct human plasma cell gene signature in subject-specific manner after trivalent influenza vaccination[@b25][@b26]. Moreover, early molecular signatures of vaccination for seasonal influenza in humans were recently investigated by using a system biology approach, so as to provide early signatures that correlated with and can be used to predict immune responses after vaccination. Even though, few reports have shown whether the immune response to vaccination correlate with glycosylation patterns of serum IgG, especially at baseline level. In order to understand the normal changes in IgG glycosylation in response to TIV, and to explore glycomic signatures for predication of vaccination efficacy, we herein analyzed the glycosylation of serum IgG and the immune responses of recipients of TIV to compare the levels of specific IgG glycans in responders and nonresponders, and to establish discernible glycosylation patterns for predicting the immune response.

Results
=======

Variations in antibody titers before and after vaccination
----------------------------------------------------------

We evaluated antibody responses of 26 healthy adult healthcare workers in our university hospital. The hemagglutination inhibition (HI) titers for each of the three components of the vaccine were determined in the sera from the inoculated subjects before (day 0) and after vaccination (day 14). Some participants had specific antibodies against the three influenza strains before vaccination (the seroprevalence rates of the antibodies to H1, H3 and B were 46.2%, 96.2%, and 34.6%, respectively) ([Figure 1A](#f1){ref-type="fig"}). After inoculation, the seroprevalence rates of their antibodies directed against the H1 and B vaccine strains increased significantly (by 100% and 84.6%, respectively) ([Figure 1A](#f1){ref-type="fig"}). A pre-vaccination HI titer \< 1:10 and a post-vaccination HI titer \> 1:40 or a pre-vaccination HI titer \> 1:10 and a minimum fourfold increase 14 days after vaccination are defined as "seroconversion", according to the guidance for the license of pandemic influenza vaccines provided by the US Food and Drug Administration[@b27]. Accordingly, the vaccinees were classified as "responders" and "nonresponders" on the basis of whether a fourfold increase of the HI titer for specific influenza strain was observed after vaccination. As can be seen from [Figure 1B](#f1){ref-type="fig"}, there was considerable variation in the magnitude of the HI responses determined for each of the influenza strains in TIV in the serum of vaccinees. The percentage seroconversion of the H1 strain was significantly higher (73.1%) than that of the H3 strain (3.8%) or the B strain (50.0%) in these subjects.

As observed in other influenza vaccination studies, a correlation between the initial HI titers (day 0) and the antibody response after vaccination was detected in our study ([Supporting information, Figure S1A, B](#s1){ref-type="supplementary-material"}). We also analyzed the correlation between the immune response and age or sex. A significant difference in the average age of the responders and nonresponders to the B strain was observed (*P* = 0.003; [Table 1](#t1){ref-type="table"}).

Questionnaire survey results
----------------------------

All 26 research subjects (13 men, 13 women) returned valid questionnaires, representing a response rate of 100%. The average age of the participants was 33.3 ± 10.8 years (range: 24--52, interquartile range = 26--37.5, [Table 2](#t2){ref-type="table"}). Only two subjects had underlying condition or history of influenza-like illness (ILI) symptoms (one with tuberculosis had developed ILI symptoms, and another one sought outpatient service for ILI symptoms twice within one year after vaccination).

Subclass-specific glycosylation analysis of human sera
------------------------------------------------------

A comprehensive analysis of the glycosylation of four subclasses of serum IgG in humans after vaccination against influenza was performed using ultra-high performance liquid chromatography coupled with electrospray ionization triple quadrupole mass spectrometer (UHPLC--ESI--QqQ MS)-based multiple reaction monitoring (MRM) method established in our laboratory (to be published elsewhere). Polyclonal IgGs (IgG1, IgG2/3 and IgG4) were isolated from sera with Protein G Sepharose™ Fast Flow beads in microcentrifuge tubes. Subclass-specific glycosylation analyses at the glycopeptide level were conducted after trypsin digestion, with the resulting glycopeptides analyzed for glycosylation profiling by using UHPLC coupled with electrospray ionization quadrupole time-of-flight mass spectrometer (UHPLC--ESI--Q-TOF MS). Since the glycopeptides derived from individual IgG subclasses have different molecular weights and distinct retention time on a C~18~ column, this allowed the unambiguous assignment of the glycoforms at the level of subclass-specific IgGs. The characterized glycopeptides were quantified with the MRM technique by using fragment ions generated from the innermost N-acetylglucosamine (GlcNAc) (*m/z* 204.1) or hexose-GlcNAc (m/z 366.1) residue as product ion, regardless of the sequences of the peptides. In total, 74 glycopeptides derived from the IgG1, IgG2/IgG3, and IgG4 subtypes were characterized and well quantified using this approach ([Figure 2](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). The glycosylation of each individual subject was evaluated using the relative abundance of each glycoform. This method allowed the detailed glycosylation analysis of IgG in human serum before and after vaccination.

Glycosylation of IgG before and after vaccination
-------------------------------------------------

To observe the changes in IgG glycosylation after vaccination, the quantitation data for the individual glycopeptides derived from IgG1, IgG2/3, and IgG4 were first visualized using principal components analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). Both the PCA and PLS-DA scores plots showed indistinguishable distributions of samples before and after vaccination, suggesting that there was no significant difference between the samples before and after vaccination in either the responder ([Figure 3B, E](#f3){ref-type="fig"}) or nonresponder group ([Figure 3A, D](#f3){ref-type="fig"}). Detail comparisons showed that relative abundance of most glycoforms of specific subject before and after vaccination were relatively stable across the time span of 14 days ([Figure 4](#f4){ref-type="fig"}).However, when using PLS-DA model, a trend separating the responders from the nonresponders to either FluB ([Figure 3C](#f3){ref-type="fig"}) or H1N1 ([Figure 3F](#f3){ref-type="fig"}) was observed, despite the samples were collected before or after vaccination. This implied that glycosylation was differentially expressed in responders and nonresponders.

Multivariate analysis of glycosylation profiles based on the antibody response
------------------------------------------------------------------------------

Since a separation trend between responders and non-responders was observed, a further orthogonal partial least squares discriminate analysis (OPLS-DA) analysis was performed, which revealed an obvious separation between responders and nonresponders, regardless of whether the samples were collected before or after vaccination ([Figure 5A, B](#f5){ref-type="fig"}). For responders and nonresponders to FluB, Q^2^Y was calculated to be 71% (four significant components, R^2^Y = 90%; [Figure 5B](#f5){ref-type="fig"}) in the OPLS-DA model, suggesting the good predictive capacity of the model. The major differences in glycosylation between the responders and nonresponders were determined from the loading plot and the VIP values for the OPLS-DA model. The potential glycosylation markers were confirmed using a univariate statistical analysis. As could be seen in [Figure 6](#f6){ref-type="fig"}, differentiated glycoforms were predominantly associated with truncated glycans of IgG1. High mannose, sialylated and bisecting glycans were also involved. These results indicated that IgG glycosylation correlated with the immune response and might be used to predict antibody titers for FluB after vaccination.

The correlation between IgG glycosylation and the HI test for H1N1 was also examined with the same multivariate analysis as that used for FluB group. As was observed for FluB, the OPLS-DA scores model showed a clear separation between responders and nonresponders ([Figure 5C](#f5){ref-type="fig"}) with a high Q^2^ value (68.6%, five significant components, R^2^Y = 92%; [Figure 5D](#f5){ref-type="fig"}), suggesting differential glycosylation patterns between the responders and nonresponders. The specific glycoforms contributing to the separation observed in the OPLS-DA scores plots were examined with the corresponding loading plot. Potential glycosylation markers with VIP \> 1 are shown in [Figure 7](#f7){ref-type="fig"}.

Because of the observed correlation between baseline titers (day 0) and the vaccination response (day 14) in our data, the different glycosylation profiles between responders and nonresponders might be attributed to variation in the initial titers. Thus we analyzed the correlation between baseline antibody titers and the relative levels of each glycoform marker for the prediction of vaccination response. Consequently, only weak correlations between the initial titers and the relative levels of 2 glycoform markers for H1 strain (IgG1-G1FS and IgG1-G1N-a, [Supporting information, Figure S3](#s1){ref-type="supplementary-material"}) were observed, but no any correlation was detected for glycomic signatures of FluB ([Figure S2](#s1){ref-type="supplementary-material"}). This indicated that the Fc glycosylation profiles may not be simply correlated with baseline antibody titer, which was further supported by PLS-DA and OPLS-DA analyses of global glycosylation profiles based on the initial antibody titers (data not show).

Discussion
==========

In the past years, several independent groups have used systems biology to predict the immune responses in humans vaccinated against influenza or yellow fever by identifying early gene 'signatures'. Some genes \[e.g., those encoding the calcium/calmodulin-dependent protein kinase type IV (CaMKIV), complement C1q subcomponent subunit B (C1qb), eukaryotic translation initiation factor 2 alpha kinase 4, and B-cell growth factor TNFRS17\] were identified as potential biomarkers predicting T-cell and B-cell responses to vaccination because they were significantly differentially expressed in the early stage of the induced immune response[@b26][@b28]. Although these biological signatures identified in the studies of early response significantly contributed to the understanding of the specific responses triggered by vaccination, their ability to predict the outcome of vaccination on the basis of baseline immunological markers has remained elusive[@b8]. Very recently, Tsang and colleagues used a systems biology approach to identify baseline immunological predictors of vaccine response. They described, for the first time, a set of baseline pre-vaccination parameters that were revealed to be predictive for the antibody response after vaccination[@b29]. These studies not only raised the prospect of monitoring immune status before vaccination[@b29], but also highlighted the need for higher levels of resolution and broader spectrum immune parameters.

Antibodies are major components of the immune system. Immunoglobulin G is the main antibody isotype existed in blood and extracellular fluid and protects the body from infection by binding many kinds of pathogens, such as representing viruses, bacteria and fungi. Recently, high baseline antibody titer was found to inversely correlate with the post-vaccination response, demonstrating that pre-existing antibodies to HA peptides are predictive to the vaccination response[@b8][@b29]. Glycosylation, which plays crucial role in the effector function of IgG, has been proven to be distinctively regulated for antigen-specific antibodies. Meanwhile, it was revealed that pre-vaccination B and T cell subpopulations were potential predictors of endpoint antibody response[@b8][@b29]. Given that distinct IgG glycosylation profiles in individuals might result from the different levels of expression and/or activities of glycan-processing enzymes[@b16] or the selective expansion of particular subsets of plasma cells with aberrant levels or activities of the corresponding enzymes[@b16][@b30][@b31], we assumed that difference in the glycosylation of IgG between responders and nonresponders might pre-existed before vaccination and thereby can serve as prediction signatures for the consequences of vaccination.

To achieve this, we used our well-established UHPLC--QqQ--MS (MRM mode) method, which analyzed glycans at the glycopeptide level and thereby allowed the analysis of subclass-specific glycosylation, for the glycosylation analyses. The use of the MRM mode facilitates high sensitive quantification with a wide linear range. In total, 74 glycopeptides from four subclasses of IgG were quantitatively examined, confirming that our method is more comprehensive than the method used in a previous vaccination study, which detected about 50 glycoforms[@b25]. Thus, the glycosylation of more glycoforms can be monitored with this high-performance method. On the other hand, unlike a previous study that investigated antigen-specific IgGs[@b25], our study focused on the analysis of global glycans of the total IgGs in circulation. Antigen-specific IgGs have been shown to be glycosylated in very distinct ways, which differs considerably from the glycosylation of the pool of total IgGs[@b32][@b33]. By contrast, glycosylation of total IgGs is a combination of genetic background and all relevant past events in the cell, hence can reflect the immune status of individual subjects more effectively.

In the previous study by Selman et al., the N-glycosylation of antigen-specific IgG showed increased galactosylation and sialylation after influenza or tetanus vaccination, whereas the total IgGs showed no significant changes after vaccination[@b25]. Consistent with that study, our results showed no significant glycosylation changes in total IgGs after vaccination. Furthermore, the composition of the glycoforms of any individual subjects was found to be very stable over a time span of 14 days of pre- and post-vaccination, despite the high inter-subject variability. This phenomena indicated genetic, including epigenetic, regulation of IgG glycosylation, as evidenced in previous study of Gordan Lauc[@b34]. Because of this, differences in the glycosylation profiles of responders and nonresponders were observed in both pre- and post-vaccination samples, which suggested the potential of glycosylation profile as predictive signatures for the vaccination response. In addition, although the baseline HI titers were reversely correlated with post-vaccination response, the differentially expressed Fc glycosylation pattern between responders and nonresponders was not directly correlated to baseline antibody titer. Thus, the correlation between vaccination response and Fc glycosylation may not be simply driven by cross-correlation with pre-vaccination titers, indicating that the glycoform markers could potentially predict post-vaccination response independent of baseline antibody titers.

Characterization of differentially expressed glycoforms between responders and nonresponders to FluB revealed glycoform-specific changes of all three subclasses of IgGs ([Figure 6](#f6){ref-type="fig"}). For example, three truncated glycoforms, i.e., 1010, 1110 and 1100 were found to be differentially expressed in responders and nonresponders to FluB ([Figure 6](#f6){ref-type="fig"}), but their changes were not in the same trend. The relative abundance of glycoform 1010 in responders was about 4 folds lower than that in nonresponders, whereas the level of 1110 and 1100 were both higher in responders than in nonresponders. This kind of glycoform-specific changes implicated a kind of strictly and subtly regulated glycosylation of IgG. Further analysis of the potential glycoform markers revealed two interesting phenomena. One is the lower levels of IgG1-G0FN (a kind of bisected glycan) and concomitant higher levels of IgG1-G1FN and G2FN in responders ([Figure 6](#f6){ref-type="fig"}), directing a relatively higher galactosylation level of the bisected glycans in responders. Another phenomenon is the overall higher levels of high mannose glycoforms in responders, including Man8, Man9 and Man9Glc1 of IgG1, as well as Man8 and Man9 of IgG2. Galactosylation is one of the most studied glycosylation feature of glycoprotein. Incomplete galactosylation of IgG could activate complement through the mannose-binding protein and therefore be involved in several pathological mechanisms[@b34]. Whereas high mannose glycoforms have been shown to have a significant impact on clinical efficacy and pharmacokinetics of therapeutic antibodies[@b35]. However, implications of the differentially expressed levels of these glycoforms between responders and nonresponders need to be explored in the future.

In addition to above features, a notable difference in the level of IgG2-G2 between responders and nonresponders was observed. This glycoform is featured by the lack of core-fucose which is attached to the first N-acetylglucosamine in the core of the N-glycan. Core-fucose could modify the conformation of Fc region and lead to dramatically decreased binding ability of Fc to FcγRIIIa[@b11][@b36], an activating Fc receptor expressed on natural killer (NK) cells. Binding of IgG to this receptor would result the initiation of ADCC. In this way, core-fucose functions as a 'safe switch' to prevent the elicitation of ADCC[@b36]. Glycoforms without core fucose are thus over 100 times more effective in triggering ADCC than fucosylated glycoforms[@b34]. Since ADCC has been proved to be an important pathway for the host to clear virus-infected cells, the higher level in IgG2-G2 in responders might indicate higher protective ability of these individuals against virus infection[@b37]. Another unusual glycosylation marker is IgG1-G1S1, which is a sialylated glycan. Terminal sialic acid on N-glycan practically reverse function of IgG and change it from pro-inflammatory into anti-inflammatory agent. It has been elucidated that specific intercellular adhesion molecule-3-grabbing nonintegrin-R1 (SIGN-R1), a C-type lectin receptor is the target of sialylated IgG and mediates its anti-inflammatory effects[@b38][@b39]. Thus the lower level of G1S1 in nonresponders might reflect the lower anti-inflammatory ability of these subjects.

Similar to those observed for response to FluB, the glycoform signatures for the prediction of response to H1N1 were majorly involved bisected glycoforms and high mannose glycoforms ([Figure 7](#f7){ref-type="fig"}). However, truncated glycoforms didn\'t show significant difference between responders and nonresponders to H1N1. This implied antigen-specific glycosylation signatures for TIV vaccination.

It should be noted that most of the predictive glycoform markers were of low-abundance species, of which the relative levels were generally below 10% or even 1%. Without monitoring these low-abundance glycoforms, the predictive model of glycosylation on vaccination efficiency may not be established. Thus, 'comprehensive' glycomic approach with capability of analyzing low-abundance glycoforms was crucial for revealing the predictive capacity of Fc glycosylation for vaccination response.

It has been demonstrated that the glycosylation profile of IgG is tightly regulated by physiological and pathological determinants in an antigen-specific manner[@b33][@b40]. Different from antigen-specific antibodies, the composition of an individual\'s glycome is a combination of genetic background and all relevant past events in the cell[@b34]. The distinct total IgG glycosylation profiles in individuals observed in our study might result from the different levels of expression and/or activities of glycan-processing enzymes[@b16] or the selective expansion of particular subsets of plasma cells with aberrant levels or activities of the corresponding enzymes[@b30]. Another possibility is that these individuals have encountered cross-reactive influenza strains during previous infections or before the current vaccination. The different glycosylation patterns observed between responders and nonresponders might be the result of a combination of these factors. The mechanism underlying the predictive capacity of glycosylation profiles for antibody titers requires further exploration. It should be noted that the baseline state of antibody glycosylation profile among individuals is likely to reflect age, at least to some extent. Thus, the strength with which these predictors apply to individuals in different age categories remains to be determined.

In summary, this is the first study of serum IgG glycosylation profiling in healthy adults receiving a TIV. A multivariate analysis of this glycosylation revealed distinct glycosylation profiles in responders and nonresponders to both FluB and H1N1. Glycosylation markers that distinguishing responders and nonresponders were identified and validated. These IgG glycan markers can be used as molecular signatures to predict antibody titers after vaccination. The relative abundance of glycoforms contributing to prediction were stable within subjects over a time span of 14 days and had up to 4 folds difference between responders and nonresponders, and thus were likely predictive because they delineated distinct baseline immune states among individuals[@b29]. Our findings raise the possibility of using such approach to discover as biomarkers of immune response potential in the clinic.

Methods
=======

This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University, and all subjects signed an informed consent form. The methods were carried out in accordance with the approved guidelines.

Sample collection
-----------------

Twenty-six healthcare workers from the First Affiliated Hospital of Guangzhou Medical University were administered the TIV in March 2011. All the subjects were healthy and were not taking any regular medication. Serum samples were collected from the participants before and 14 days after vaccination.

The TIV contained the following strains, which were recommended by WHO as the influenza vaccines for use in the 2010--2011 and 2011--2012 northern-hemisphere influenza seasons: A/California/7/2009 (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus.

Hemagglutination inhibition test (HI)
-------------------------------------

The strains A/California/07/2009 (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus, to be used as antigens, were isolated from clinical samples by our laboratory and identified by sequencing their hemagglutinin and neuraminidase genes. All serum samples were tested by HI, as previously described[@b41]. Briefly, serum samples and red blood cells from chickens (Genebase Co., Guangzhou, China) were treated with receptor-destroying enzyme (Denka Seiken Co., Tokyo, Japan), according to the instructions for eliminating non-specific agglutinins and inhibitors before testing. All samples were tested in twofold dilutions from 1:10 to 1:1280. The highest dilution of serum that prevents hemagglutination is considered to be the HI titer of the serum.

Questionnaire
-------------

A survey was conducted by questionnaire in June of 2012. All the vaccine recipients enrolled in the study were asked whether they had developed influenza-like symptoms or had been hospitalized in the year after their inoculation. The questionnaire was administered to the enrolled subjects, all of whom answered all the questions, and all the information was treated confidentially.

IgG purification from serum with Protein G
------------------------------------------

Total IgGs were isolated from human serum with Protein G Sepharose™ 4 Fast Flow beads (90 μm; GE Healthcare, Uppsala, Sweden). The Protein G beads (50 μL) were firstly washed twice with 250 μL of binding buffer (20 mM sodium phosphate, pH 7.0). The mixture including the beads, 250 μL of binding buffer, and 10 μL of serum was then mixed by inversion and incubated at room temperature for 1 h. After incubation, the beads were washed twice with 250 μL of binding buffer. The captured IgGs were eluted twice with 200 μL of elution buffer (0.1 M glycine buffer, pH 2.7) and then neutralized with 30 μL of neutralizing buffer (1 M Tris-HCl, pH 9.0). The buffer from the captured IgGs was exchanged with trypsin digestion buffer (50 mM ammonium bicarbonate in 15% acetonitrile, pH 7.4) and concentrated to a final volume of 30 μL with a 30 K centrifugal filter unit (Millipore, Carrigtwchill, County Cork, Ireland).

IgG digestion with trypsin
--------------------------

Trypsin Gold (mass spectrometry grade; Promega, Wisconsin, USA) was first reconstituted in 50 mM acetic acid to a final concentration of 1 μg/μL and then further diluted to 0.05 μg/μL with trypsin digestion buffer. The trypsin solution (10 μL) was added to the IgG samples and the mixtures were diluted to a final volume of 100 μL with trypsin digestion buffer and incubated overnight at 37°C. After incubation, 0.5 μL of formic acid was added to quench the digestion reaction. The samples were centrifuged at 14000 g for 5 min, and the supernatant was stored at −80°C until analysis.

Ultrahigh-performance liquid chromatography (UHPLC)--mass spectrometry (MS) analysis of glycopeptides
-----------------------------------------------------------------------------------------------------

UHPLC was performed with an Agilent 1290 Infinity UHPLC system (Agilent Technologies, Santa Clara, CA, USA), equipped with a binary solvent delivery system and a standard autosampler. Chromatography was performed on an Agilent ZORBAX Eclipse Plus C~18~ column (2.1 × 150 mm, 1.8 μm), and the column temperature was maintained at 40°C. The mobile phase consisted of 0.1% formic acid in distilled water (A) and 0.1% formic acid in acetonitrile (B). The following optimized linear gradient was applied: 0--8 min, 2%--6% B; 8--16 min, 6%--10% B; 16--20 min, 10%--35% B; 20--25 min, 35%--50% B; 25--30 min, 50%--100% B; 30--32 min, 100% B; followed by the equilibration of the column for 8 min before the next run. The flow rate was 0.3 mL/min and the injection volume was 5 μL.

The UHPLC system was coupled to an Agilent 6490 Triple Quadrupole LC/MS System (Agilent Technologies) equipped with an iFunnel and an Electrospray Ion Source (ESI) with Agilent Jet Stream Technology. Nitrogen was used as the nebulizing gas (40 psi), the drying gas (16 L/min, 250°C), and the sheath gas (11 L/min, 400°C). The capillary voltage was set to 4000 V and the nozzle voltage to 1500 V. The mass analyzer was operated in positive mode and in the multiple reaction monitoring (MRM) mode with a dwell time of 10 s, a fragmentor voltage of 380 V, and a collision energy of 18 V. The triplely charged ions \[M+3H\]^3+^ of the glycopeptides ([Table 3](#t3){ref-type="table"}) were set as precursor ions, and fragment ions generated from N-acetylglucosamine (GlcNAc) at *m/z* 204.1 or hexose-GlcNAc at *m/z* 366.1 were employed as product ions for MRM transitions.

Multivariate analysis
---------------------

All samples were prepared in duplicate and subjected to LC-MS analyses in duplicate. The samples were analyzed using the software of Agilent MassHunter Quantitative Analysis (version B.05.00, Agilent Technologies). The intensity of each peak obtained was normalized as the percentage peak intensity relative to the total peak intensity in that sample. Multivariate statistical data analyses, including a principal components analysis (PCA), partial least-squares-discriminant analysis (PLS-DA), and orthogonal partial least squares discriminate analysis (OPLS-DA), were performed using the SIMCA 13.0 software (Umetrics, Umea, Sweden). The scores plot of the PCA displays the general clustering, trends, or outliers in the observations (or samples), whereas PLS-DA and OPLS-DA are supervised methods capable of removing information from an input data set X that is unrelated to the response set Y to improve the interpretation of the variations responsible for the separation. The R^2^Y and Q^2^Y values indicate the goodness of the OPLS-DA model. R^2^Y provides an estimate of how well the model fits the Y data, whereas Q^2^Y is an estimate of how well the model predicts Y. Cumulative values of R^2^Y and Q^2^Y close to 1 indicate an excellent model.

The major differences in glycosylation between the responders and nonresponders were determined based on loading plots and the variable importance parameters (VIPs) for each pattern recognition model. The loading plots display the correlation between the X variables, in the first dimension, or the residuals of the X variables in subsequent dimensions. The VIP indicates the effect on class membership. A VIP value larger than 1 is more successfully explains Y than smaller VIP values. In general, the glycosylation that contributed to the variation in the present study was identified by ranking the VIP values, and further validated with a univariate analysis (Student\'s t test).

Statistical analysis
--------------------

The statistical software SPSS 13.0 (SPSS, Chicago, IL, USA) was used for all statistical analyses. Quantitative characteristics are presented as means ± SD. Data that were normally distributed were compared using analysis of variance (ANOVA). All hypothesis testing was two-sided and P \< 0.05 was defined as significant.
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![MRM chromatogram of representative glycopeptides from different IgG subclasses in human serum.\
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![PCA and PLS-DA scores plot of the glycosylation profiles of subjects before and after vaccination.\
(A--C) Analyses based on the antibody response to B strain. (D--F) Analyses based on antibody response to H1 strain.](srep07648-f3){#f3}
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![Multivariate statistical results for IgG glycosylation in responders and nonresponders to FluB (A,B) and H1N1 (C,D) (HI test).\
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![Box plots depicting changes in the relative abundances of the potential glycoforms signatures for responders (*n* = 13) and nonresponders (*n* = 13) to FluB.](srep07648-f6){#f6}
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###### Characteristics of participants with or without immune response after vaccination

                                         A/California/07/2009 (H1N1)   A/Perth/16/2009 (H3N2)   B/Brisbane/60/2008                                              
  ------------------------------------- ----------------------------- ------------------------ -------------------- ------- ----------------------------------- -----
  Positive[§](#t1-fn2){ref-type="fn"}            34.5 ± 11.6                    9/10                    24            0/1               28.3 ± 4.17              7/6
  Negative[¶](#t1-fn3){ref-type="fn"}            33.6 ± 9.0                     4/3                34.7 ± 10.8       13/12              40.2 ± 12.1              6/7
  *p* value                                         0.85                        ---                    ---            ---    0.003[\*](#t1-fn4){ref-type="fn"}   ---

^†^M, male; F, female.

^§^HI titers of 1:40 or more with an increase of at least fourfold 14 days after vaccination.

^¶^HI titers increased less than fourfold 14 days after vaccination.

\**p*\< 0.01.

###### Responses to the questionnaire about the efficacy of the influenza vaccine during the first year

  Description                                                                                    Subject Number (%)
  --------------------------------------------------------------------------------------------- --------------------
  Current smoker                                                                                      2 (7.7)
  History of secondhand smoker                                                                        8 (30.8)
  Underlying conditions                                                                                   
  Cardiac disease                                                                                      0 (0)
  Lung disease[†](#t2-fn1){ref-type="fn"}                                                              0 (0)
  Diabetes mellitus                                                                                    0 (0)
  Cerebral apoplexy                                                                                    0 (0)
  Tuberculosis                                                                                        1 (3.8)
  Pneumoconiosis                                                                                       0 (0)
  Other chronic diseases[‡](#t2-fn1){ref-type="fn"}                                                    0 (0)
  Developed ILI symptoms during the first year after vaccination [§§](#t2-fn1){ref-type="fn"}         2 (7.7)

Notes: †Lung diseases are defined as chronic obstructive pulmonary disease, asthma, bronchiectasis, interstitial lung disease, and cancer. ‡Other chronic diseases affecting the renal system, endocrine system (excluded diabetes), hematological system, nervous system (excluding cerebrovascular disease), and gastrointestinal system. §§ ILI symptoms were defined as fever (\> 38°C) with two or more of the following symptoms: headache, chill, myalgia or joint pain, fatigue, coryza, sore throat and dry cough.

###### MS data of glycopeptides of human serum IgG detected in this study

  Glycan[a](#t3-fn1){ref-type="fn"}    Structure   IgG1 P01857 [b](#t3-fn2){ref-type="fn"}EEQYN~297~STYR [b](#t3-fn2){ref-type="fn"}   IgG2/IgG3 P01859 [b](#t3-fn2){ref-type="fn"}EEQFN~297~STFR [b](#t3-fn2){ref-type="fn"}   IgG4 P01861 [b](#t3-fn2){ref-type="fn"}EEQFN~297~STYR [b](#t3-fn2){ref-type="fn"}                          
  ----------------------------------- ----------- ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------- ----------- -----------
  Peptide only                                                                         1188.5047                                                                              397.1682                                                                              1156.5149                                       386.5050    1172.5098   391.8366
  G0                                                                                   2486.9807                                                                              830.0008                                                                              2454.9909                                       819.3376    2470.9858   824.6692
  G0N                                                                                  2690.0615                                                                              897.6940                                                                              2658.0717                                       887.0307    2674.0666   892.3623
  G0FN                                                                                 2836.1180                                                                              946.3799                                                                              2804.1282                                       935.7167    2820.1231   941.0483
  G0F                                                                                  2633.0386                                                                              878.6868                                                                              2601.0488                                       868.0235    2617.0437   873.3552
  G1                                                                                   2649.0335                                                                              884.0184                                                                              2617.0437                                       873.3552    2633.0386   878.6868
  G1N                                                                                  2852.1141                                                                              951.7116                                                                              2820.1243                                       941.0483    2836.1192   946.3799
  G1FN                                                                                 2998.1708                                                                             1000.3975                                                                              2966.1810                                       989.7343    2982.1759   995.0659
  G1FNS                                                                                3289.2662                                                                             1097.4293                                                                              3257.2764                                       1086.7661   3273.2713   1092.0977
  G1NS                                                                                 3143.2083                                                                             1048.7434                                                                              3111.2197                                       1038.0801      \-          \-
  G1F                                                                                  2795.0914                                                                              932.7044                                                                              2763.1016                                       922.0411    2779.0965   927.3728
  G1FS                                                                                 3086.1869                                                                             1029.7362                                                                              3052.1970                                       1019.0729   3070.1919   1024.4046
  G2                                                                                   2811.0864                                                                              938.0361                                                                              2779.0965                                       927.3728    2795.0914   932.7044
  G2N                                                                                  3014.1669                                                                             1005.7292                                                                              2982.1771                                       995.0659    2998.1720   1000.3975
  G2FN                                                                                 3160.2236                                                                             1054.4151                                                                              3128.2338                                       1043.7519   3144.2287   1049.0835
  G2NS                                                                                 3305.2624                                                                             1102.7610                                                                                 \-                                              \-          \-          \-
  G2F                                                                                  2957.1443                                                                              986.7220                                                                              2925.2544                                       976.0587    2941.1494   981.3904
  G2FS                                                                                 3248.2397                                                                             1083.7538                                                                              3216.2499                                       1073.0906   3232.2448   1078.4222
  G2S                                                                                  3102.1818                                                                             1035.0679                                                                              3070.1919                                       1024.4046   3086.1869   1029.7362
  G2S2                                                                                    \-                                                                                     \-                                                                                 3361.2874                                       1121.4364                    
  Man8                                                                                 2891.0861                                                                              964.7026                                                                              2859.0963                                       954.0394    2875.0912   959.3710
  Man9                                                                                 3053.1389                                                                             1018.7202                                                                              3021.1491                                       1008.0570   3037.1440   1013.3886
  Man9Glc1                                                                             3215.1917                                                                              1072.778                                                                                 \-                                              \-          \-          \-
  0100                                                                                    \-                                                                                     \-                                                                                 2194.8902                                       732.6373    2210.8851   737.9689
  1000                                                                                 2283.9015                                                                              762.3077                                                                              2251.9117                                       751.6444    2267.9066   756.9761
  1010                                                                                 2445.9543                                                                              816.3253                                                                              2413.9645                                       805.6620    2429.9592   810.9937
  1100                                                                                 2429.9594                                                                              810.9937                                                                              2397.9696                                       800.3304    2413.9645   805.6620
  1110                                                                                 2592.0122                                                                              865.0113                                                                              2560.0224                                       854.3480    2576.0173   859.6797
  1111                                                                                    \-                                                                                     \-                                                                                 2851.1178                                       951.3798       \-          \-

^a^Glycan structures are presented in forms of number of galactoses (G0, G1, G2), fucose (F), bisecting N-acetylglucosamine (N) and N-acetylneuraminic acid, sialic acid (S).

^b^SwissProt entry number.

[^1]: These authors contributed equally to this work.
